There are thousands of rare diseases, but they each affect so few patients that diagnosis and treatment can be delayed by years. Researchers examined how machine learning has been studied in rare diseases and identified areas of opportunity where future studies can improve care and treatment of rare diseases.
The diagnosis, treatment, and prognosis of rare diseases can be improved, and current use of the technology in rare diseases can be used to guide future research and uses of it, according a study published in Orphanet Journal of Rare Diseases.
Although there are thousands of rare diseases, the majority affect fewer than 1 patient in a 1 million.
“This means that, for most rare diseases, even experienced physicians with a lot of patient contact never see a single patient in their lifetime,” the authors explained.
Correctly diagnosing rare diseases can be difficult, and patients with rare diseases may be misdiagnosed for years before they receive the correct diagnosis.
“Improving the diagnosis and treatment of rare diseases is therefore an important public health concern,” they added.
There are networks that bring together data and expertise so providers can easily access and exchange relevant information. Some of these knowledge bases include Orphanet, RD-Connect, the European Reference Networks, the European Joint Programme on Rare Diseases, the Undiagnosed Diseases Network, and a new German national initiative, the Collaboration on Rare Diseases.
In addition to these collaborative efforts, advances in technology, such as artificial intelligence and machine learning, can improve time to diagnosis and treatment decisions. A computer can sift through huge quantities of digital information and extract and use that information in meaningful ways, while a human cannot memorize information about thousands of rare diseases.
The authors sought to understand how machine learning was being used in rare diseases and identify areas of future work by pointing to gaps in research or promising areas of study. They performed a scoping review, which is used for synthesizing research evidence and answering broader, topic-focused questions beyond those related to the effectiveness of treatments or interventions.
The authors systematically searched literature on PubMed using terms such as “machine learning,” “artificial intelligence,” “rare disease,” and “orphan disease,” as well as the names of 381 specific rare diseases. Studies published between January 1, 2010, and December 31, 2019, were included. A total of 211 articles were included in the final analysis, with studies originating from 32 countries, although a plurality (91 studies, 43.1%) were from the United States.
Among the 211 studies, only 74 rare diseases were investigated, with the most frequently investigated diseases being amyotrophic lateral sclerosis (7.6%), systemic lupus erythematosus (6.6%), moderate and severe traumatic brain injury (5.7%), and cystic fibrosis (4.7%).
According to the authors, some diseases were overrepresented (ie, rare systemic or rheumatologic diseases, rare respiratory diseases, rare cardiac diseases, and rare gastroenterologic diseases) and others were underrepresented (ie, rare developmental defects during embryogenesis, rare inborn errors of metabolism, rare skin diseases and rare endocrine diseases) in the studies based on the distribution of disease groups investigated with the expected distribution.
In general, though, the authors found that diseases with a lower prevalence received less attention and diseases with a higher prevalence were investigated more frequently.
Machine learning was most often used in the studies for diagnosis (40.8%) or prognosis (38.4%). In comparison, studies aimed at improving treatment were scarce (4.7%). The authors noted that since classification and prediction are typical applications of machine learning, it made sense that diagnosis and prognosis were the most common uses.
“However, machine learning can also play an important role in improving the treatment of rare diseases, and future studies could focus more on this aspect, for example by using machine learning to accelerate drug development,” the authors wrote.
Reference
Schaefer J, Lehne M, Schepers J, Prasser F, Thun S. The use of machine learning in rare diseases: a scoping review. Orphanet J Rare Dis. 2020;15(1):145. doi:10.1186/s13023-020-01424-6
Real-World Data Show Poor Outcomes Among Patients With ACS and Blood Cancers
December 8th 2023A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Patients With RA in Remission Withdrawing From TNF Inhibition Show Flare Increases
December 8th 2023New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued a tumor necrosis factor inhibitor (TNFi).
Read More
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More